The agency has stepped up its campaign against drugmakers' improper listing of patents in the FDA's Orange Book, which it ...
The antitrust cop says that the more than 300 patent listings stall generic competition, keeping prices high for diabetes drugs, inhalers and more. The Federal Trade Commission is challenging ...
The U.S. Federal Trade Commission (FTC) is not done with its crackdown on what it views as improper listing of patents with the FDA. After an initial round of challenges launched in November ...
The U.S. Federal Trade Commission (FTC) announced last week that it is, for the second time, disputing hundreds of “junk” ...
At the center of the issue is the Orange Book, an FDA publication containing patents relevant to brand-name pharmaceuticals. If a brand-name manufacturer decides to contest a challenge to an ...
U.S. Senator Bernie Sanders commended the Biden administration for its efforts to combat pharmaceutical companies’ ...
The FTC recently announced that it has sent another round of letters disputing additional patent listings in the FDA’s Orange Book. With this latest action, the FTC has now challenged hundreds of ...
The Federal Trade Commission said it is challenging hundreds of alleged "junk" patents held by pharmaceutical companies for 20 brand-name drugs, including Novo Nordisk's blockbuster diabetes drugs ...
Federal antitrust officials have redoubled efforts to challenge what they see as improper pharma patent listings that delay the market entry of generic drugs. This week, the Federal Trade Commission ...
The U.S. Federal Trade Commission expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings pertaining to 20 different brand-name treatments for ...
The U.S. Federal Trade Commission expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings pertaining to 20 different brand-name treatments for ...